文献速递消化系统肿瘤

AJCC第8版胰腺腺癌分期预后价值评估及III期细分建议

Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?
PubMed 文献 · Eur J Cancer · 2018-10-13

结果显示第8版对N1与N2的区分有预后意义,但同属III期的N2与T4患者生存差异显著,故建议将III期细分为IIIA(T1-3N2M0)和IIIB(T4NanyM0)。

要点

  • 第8版分期中N1(1-3枚阳性淋巴结)与N2(≥4枚阳性淋巴结)生存差异显著(p < 0.001)。
  • 同属III期的N2患者生存优于T4患者(p = 0.038)。
  • 建议将III期细分为IIIA(T1-3N2M0)和IIIB(T4NanyM0)。

核心结论

  • AJCC第8版分期较前版有优势,但III期中N2与T4患者预后不同,建议细分III期。

主要发现

  • 淋巴结阴性患者中,第8版T1、T2、T3组生存无显著差异。
  • 第8版N1(1-3枚阳性淋巴结)与N2(≥4枚阳性淋巴结)患者生存率差异显著(p < 0.001)。
  • 同属III期的N2患者生存率优于T4患者(p = 0.038)。
  • 新分期系统在各期分布更均衡且不损失预后准确性。

关键数值与推荐

  • 建议将III期分为IIIA(T1-3N2M0)和IIIB(T4NanyM0)。

临床怎么用

  • 临床分期时可关注N2与T4的预后差异,考虑III期亚分期对治疗决策的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There have been several proposed changes for the 8th edition of the American Joint Commission on Cancer (AJCC) for pancreatic adenocarcinoma. The aim of this study was to evaluate the prognostic value of the new staging system for patients with pancreatic adenocarcinoma, especially in stage III patients. METHODS: We analysed the data of patients newly diagnosed with pancreatic adenocarcinoma between 2008 and 2016 at our hospital. Patients were staged according to 7th edition AJCC criteria, as well as the new 8th edition staging system. The pathologic stage was used in the surgical cases, and the clinical stage, determined by radiographic findings, was used in the unresectable cases. RESULTS: Five hundred two patients were identified who met the inclusion criteria. In node-negative patients, there were no significant differences in survival among T 1, 2 and 3 groups according to the 8th edition. The survival rates of patients with N1 (1-3 positive nodes) and N2 (≥4 positive nodes) disease, according to 8th edition, were significantly different (p < 0.001). Although N2 and T4 patients are both stage III according to the new staging system, N2 patients had a better survival rate than T4 patients (p = 0.038). The new staging system stratifies patients more evenly across stages without sacrificing the prognostic accuracy. CONCLUSIONS: The AJCC 8th edition has some advantages over the previous version. However, patients with N2 and T4, who have been integrated into stage III, showed different treatment modalities and prognoses, and we proposed dividing stage III into IIIA (T1-3N2M0) and IIIB (T4NanyM0).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Song M, Yoon SB, Lee IS, et al. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? Eur J Cancer. 2018. PMID: 30326370. doi:10.1016/j.ejca.2018.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。